ACIU insider trading
NasdaqGM HealthcareAC Immune SA — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About AC Immune SA
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Company website: www.acimmune.com
ACIU insider activity at a glance
FilingIQ has scored 3 insider transactions for ACIU since Apr 15, 2026. The most recent filing in our index is dated May 15, 2026.
Across the full history, 1 open-market purchases
and 2 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ACIU?
- FilingIQ tracks 3 Form 4 insider transactions for ACIU (AC Immune SA), covering filings from Apr 15, 2026 onwards. 3 of those were filed in the last 90 days.
- Are ACIU insiders net buyers or net sellers?
- Across the full Form 4 history for ACIU, 1 transactions (33%) were open-market purchases and 2 (67%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ACIU insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ACIU in?
- AC Immune SA (ACIU) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $306.85M.
Methodology & sources
Every ACIU insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.